Is Definium Therapeutics, Inc. (DFTX) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 1.2% / 30% | 15.5% / 30% | 0.0% / 30% | N/A | ✓ HALAL |
| DJIM | 1.2% / 33% | 15.5% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| MSCI | 7.2% / 33% | 90.6% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 1.2% / 33% | 15.5% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| FTSE | 7.2% / 33% | 90.6% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -64.1% | |
| Return on Assets (ROA) | -28.0% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$132M |
| Free Cash Flow | -$132M |
| Total Debt | $41M |
| Debt-to-Equity | 12.2 |
| Current Ratio | 6.3 |
| Total Assets | $440M |
Price & Trading
| Last Close | $18.94 |
| 50-Day MA | $17.43 |
| 200-Day MA | $12.39 |
| Avg Volume | 1.8M |
| Beta | 2.7 |
|
52-Week Range
$4.70
| |
About Definium Therapeutics, Inc. (DFTX)
Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Definium Therapeutics, Inc. in January 2026. Definium Therapeutics, Inc. is headquartered in New York, New York.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Definium Therapeutics, Inc. (DFTX) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Definium Therapeutics, Inc. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Definium Therapeutics, Inc.'s debt ratio?
Definium Therapeutics, Inc.'s debt ratio is 1.2% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 7.2%.
What are Definium Therapeutics, Inc.'s key financial metrics?
Definium Therapeutics, Inc. has a market capitalization of $1.8B. Return on equity stands at -64.1%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.